» Articles » PMID: 34874499

Feasibility of Glioblastoma Tissue Response Mapping with Physiologic BOLD Imaging Using Precise Oxygen and Carbon Dioxide Challenge

Overview
Journal MAGMA
Publisher Springer
Date 2021 Dec 7
PMID 34874499
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Innovative physiologic MRI development focuses on depiction of heterogenous vascular and metabolic features in glioblastoma. For this feasibility study, we employed blood oxygenation level-dependent (BOLD) MRI with standardized and precise carbon dioxide (CO) and oxygen (O) modulation to investigate specific tumor tissue response patterns in patients with newly diagnosed glioblastoma.

Materials And Methods: Seven newly diagnosed untreated patients with suspected glioblastoma were prospectively included to undergo a BOLD study with combined CO and O standardized protocol. %BOLD signal change/mmHg during hypercapnic, hypoxic, and hyperoxic stimulus was calculated in the whole brain, tumor lesion and segmented volumes of interest (VOI) [contrast-enhancing (CE) - tumor, necrosis and edema] to analyze their tissue response patterns.

Results: Quantification of BOLD signal change after gas challenges can be used to identify specific responses to standardized stimuli in glioblastoma patients. Integration of this approach with automatic VOI segmentation grants improved characterization of tumor subzones and edema. Magnitude of BOLD signal change during the 3 stimuli can be visualized at voxel precision through color-coded maps overlayed onto whole brain and identified VOIs.

Conclusions: Our preliminary investigation shows good feasibility of BOLD with standardized and precise CO and O modulation as an emerging physiologic imaging technique to detail specific glioblastoma characteristics. The unique tissue response patterns generated can be further investigated to better detail glioblastoma lesions and gauge treatment response.

Citing Articles

Cerebrovascular Reactivity Mapping in Brain Tumors Based on a Breath-Hold Task Using Arterial Spin Labeling.

Calvo-Imirizaldu M, Solis-Barquero S, Aramendia-Vidaurreta V, Garcia de Eulate R, Dominguez P, Vidorreta M NMR Biomed. 2025; 38(3):e5317.

PMID: 39844376 PMC: 11754703. DOI: 10.1002/nbm.5317.


Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis.

Valenzuela-Fuenzalida J, Moyano-Valarezo L, Silva-Bravo V, Milos-Brandenberg D, Orellana-Donoso M, Nova-Baeza P J Clin Med. 2024; 13(12).

PMID: 38929990 PMC: 11204640. DOI: 10.3390/jcm13123460.


Transient deoxyhemoglobin formation as a contrast for perfusion MRI studies in patients with brain tumors: a feasibility study.

Stumpo V, Sayin E, Bellomo J, Sobczyk O, van Niftrik C, Sebok M Front Physiol. 2024; 15:1238533.

PMID: 38725571 PMC: 11079274. DOI: 10.3389/fphys.2024.1238533.


Advances in PET imaging of cancer.

Schwenck J, Sonanini D, Cotton J, Rammensee H, Fougere C, Zender L Nat Rev Cancer. 2023; 23(7):474-490.

PMID: 37258875 DOI: 10.1038/s41568-023-00576-4.


Hemodynamic Imaging in Cerebral Diffuse Glioma-Part A: Concept, Differential Diagnosis and Tumor Grading.

Guida L, Stumpo V, Bellomo J, van Niftrik C, Sebok M, Berhouma M Cancers (Basel). 2022; 14(6).

PMID: 35326580 PMC: 8946242. DOI: 10.3390/cancers14061432.


References
1.
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn J, Minniti G . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170-186. PMC: 7904519. DOI: 10.1038/s41571-020-00447-z. View

2.
Wen P, Weller M, Quant Lee E, Alexander B, Barnholtz-Sloan J, Barthel F . Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020; 22(8):1073-1113. PMC: 7594557. DOI: 10.1093/neuonc/noaa106. View

3.
Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

4.
Le Rhun E, Preusser M, Roth P, Reardon D, van den Bent M, Wen P . Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019; 80:101896. DOI: 10.1016/j.ctrv.2019.101896. View

5.
Mazurowski M . Radiogenomics: what it is and why it is important. J Am Coll Radiol. 2015; 12(8):862-6. DOI: 10.1016/j.jacr.2015.04.019. View